Src/FAK and EGFR converge on common downstream pathways [38], which may account for the observed antitumor activity in patients with advanced NSCLC co-treated with inhibitors of both signaling pathways [31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.